The pro-fibrogenic role of SerpinB3 was also investigated both in vitro and in animal models of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Here, SERPINB3 is linked to metabolic dysfunction-associated steatotic liver disease.